| 000 | 00000nam##2200000za#4500 |
| 001 | 9.615043 |
| 003 | CaOODSP |
| 005 | 20210615100949 |
| 007 | ta |
| 008 | 150406|2000||||xxc||||| f|0| 0 eng|d |
| 020 | |a0-662-28442-9 |
| 040 | |aCaOODSP|beng |
| 043 | |an-cn--- |
| 086 | 1 |aH42-2/67-15-1999E |
| 110 | 1 |aCanada. |bHealth Products and Food Branch. |
| 245 | 10|aAddendum to "Dose selection for carcinogenicity studies of pharmaceuticals" : |baddition of a limit dose and related notes |
| 260 | |aOttawa - Ontario : |bHealth Canada. |c2000. |
| 300 | |ai, 2p. ; |c28 cm. |
| 490 | 1 |aGuidance for industry|vICH topic S1C (R) |
| 563 | |aLoose-leaf |
| 590 | |a01-25|b2001-06-22 |
| 690 | 07|aTesting|2gcpds |
| 690 | 07|aCancer|2gcpds |
| 690 | 07|aDrugs|2gcpds |
| 690 | 07|aPharmaceutical industry|2gcpds |
| 776 | 0#|tAddendum to "Dose selection for carcinogenicity studies of pharmaceuticals" : |w(CaOODSP)9.573937 |
| 830 | #0|aGuidance for industry ;|vICH topic S1C (R)|w(CaOODSP)9.514730 |